Research Paper

Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B

Do-Yeon Cho a,b,* , Kyle J. Hoffman a , Gobind S. Gill a , Dong-Jin Lim a , Daniel Skinner a , Calvin Mackey a , Steven M. Rowe b,c , Bradford A. Woodworth a,b,** ,d

a Department of Otolaryngology Head & Neck Surgery, University of Alabama at Birmingham, Birmingham, AL, USA
b Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA
c Departments of Medicine, Pediatrics, Cell Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA

Received 15 January 2017; accepted 23 January 2017
Available online 7 March 2017

Abstract Objective: Amphotericin B (AMB), a potent antifungal agent, has been employed as topical and systemic therapy for sinonasal fungal infections. A novel formulation of nanodisc (ND) containing super aggregated AMB (ND-AMB) for the treatment of fungal infections has been recently developed to provide greater protection from AMB toxicity than current, clinically approved lipid-based formulations. The objective of the current study was to evaluate the safety and potency of ND-AMB for sinonasal delivery using an in vitro model.

Methods: Human sinonasal tissue was harvested during endoscopic sinus surgery and grown at air–liquid interface until well-differentiated. Cultures were exposed to ND-AMB vs AMB and changes in K+ permeability and resistance were measured and recorded via Ussing chamber.
Mucociliary clearance; Ciliary beat frequency

Introduction

Since fungi are present throughout the environment, human exposure is inevitable and normal respiration routinely deposits fungal elements within the nose and paranasal sinuses. In most instances, the presence of fungal elements in the nose has no consequences. However, fungi can contribute to the pathogenesis of rhinosinusitis (fungal rhinosinusitis) in tissue-invasive or noninvasive conditions. Regional variation in incidence has been reported, with the southern part of United States particularly endemic. Fungal rhinosinusitis (FRS) has been categorized primarily based on whether the fungus invades local tissues or not, a characteristic intimately associated with the status of the host’s immune system. Patients who are immunocompromised are highly susceptible to invasive fungal sinusitis (IFS), and despite prophylactic treatment, mortality due to fungal infections remains high. With the use of newer and more potent chemotherapeutic agents and regimens, more patients are now susceptible to fatal invasive fungal sinusitis.3

Amphotericin B (AMB) is a potent antifungal agent and topical delivery of AMB may have significant advantages over systemic intake (either intravenous or oral) including the avoidance of systemic and infusion-related toxicities. However, AMB affects the integrity of apical cell membranes in human nasal epithelial cells and can be toxic at higher doses. Oda et al8 have developed a novel formulation of NanoDisk (ND) containing super aggregated AMB for the treatment of fungal infections. NanoDisk amphotericin B (ND-AMB) provided greater protection from AMB toxicity by protecting against apical cell K+ permeability while maintaining uncompromised antifungal property compared to AMB. ND-AMB could provide a novel topical therapy for sinonasal fungal diseases.

Methods

Amphotericin

Amphotericin (AMB; Sigma-Aldrich, St. Louis, MO) was prepared according to manufacturer’s instructions. ND-AMB was provided as a gift from the Oda laboratory and preparation of ND-AMB has been described previously by Michael Oda.8

Primary cell culture

Institutional Review Board and Institutional Animal Care and Use Committee approval were obtained prior to initiating these studies. Human septonasal epithelial cells (HSNE) were harvested, grown on Costar 6.5-mm diameter permeable filter supports (Corning Life Sciences, Lowell, MA), and submersed in culture medium as previously described.9–12 Media was removed from the monolayers on day 4 after the epithelium reached confluence, and cells fed via the basal chamber. Differentiation and ciliogenesis occurred in all cultures within 10–14 days. Cultures were used for experiments when well-differentiated with widespread ciliogenesis with transepithelial resistances (Rt) > 100 Ω cm2.

Ussing chamber analysis

Transwell inserts (Costar) were mounted in Ussing chambers to investigate pharmacologic manipulation of vectorial ion transport as previously described.13–15 Transepithelial current measurements were performed with Easy Mount Ussing chambers (Physiologic Instruments, San Diego, CA) with an apical-to-basolateral directed gradient for K+.6,16 High K+ buffer in the apical reservoir was (in mmol/L): 120 KCl, 20 NaHCO3, 5 KHC03, 1.2 NaH2PO4, 5.6 glucose, 2.5 CaCl2, and 1.2 MgSO4. The basolateral reservoir buffer was (in mmol/L): 120 NaCl, 20 NaHCO3, 5 KHC03, 1.2 NaH2PO4,
5.6 glucose, 2.5 CaCl₂, and 1.2 MgSO₄. All experiments were conducted at 37 °C and solutions were continuously gassed with 95% air, 5% CO₂ resulting in pH 7.4. Trans-epithelial voltage was clamped to 0 mV using a standard four electrode voltage clamp and gradient-driven K⁺ current was recorded at 5 Hz by an analog-to-digital board (DATAQ Instruments, Inc. Akron, OH) connected to a personal computer. Positive currents were defined as cation movement from apical to basal reservoir. AMB or ND-AMB was introduced to the apical reservoir of the Ussing chamber and transepithelial K⁺ was allowed to reach equilibrium.

**Lactate dehydrogenase (LDH) assay**

To determine the cytotoxicity of cells after exposure to AMB or ND-AMB (18 h), culture medium was tested for the presence of released lactate dehydrogenase (LDH). A 96-well LDH Cytotoxicity Assay Kit (Cayman Chemical Company, Ann Arbor, MI) was used, with the following modifications: on the day of the assay, 100 µL of culture medium was removed and added to 100 µL of Reaction Solution. Absorbance at 490 nm was obtained with Exp Precision Microplate Reader (Molecular Devices, Sunnyvale, CA). We measured the LDH levels 30 min after exposure. Triton X-100 (10%) was used as a positive control (maximum release of LDH) and cell medium (without phenol) was used as a negative control (spontaneous release of LDH). % Cytotoxicity of test sample was calculated based on below formula:

\[
\% \text{Cytotoxicity} = \frac{(\text{Experimental value}) - (\text{Spontaneous release})}{(\text{Maximum release}) - (\text{Spontaneous release})} \times 100
\]

**Ciliary beat frequency**

Images were visualized using a 20× objective on an inverted scope (Fisher Scientific, Pittsburgh, PA). Data was captured using a Model A602F-2 Basler area scan high-speed monochromatic digital video camera (Basler AG, Ahrensburg, Germany) at a sampling rate of 100 frames per second and a resolution of 640 × 480 pixels. Images were analyzed using the Sisson-Ammons Video Analysis (SAVA) system version 2.16 and virtual instrumentation software for CBF monitoring. All recordings were made at 200× magnification. Experiments were all performed at ambient temperature (23 °C). A baseline recording of CBF was conducted for each cell monolayer prior to apical administration of test solution [AMB (75 µg/ml) vs ND-AMB (75 µg/ml)] and compared to the corresponding control using vehicle alone. Whole field analysis was performed with each point measured representing one cilium and analysis was normalized to fold-change over baseline.

**Preparation of Aspergillus fumigatus conidia and exposure to AMB or ND-AMB**

A. fumigatus isolate 13073 (ATCC, Manassas, Virginia, United States) was used in all experiments. The frozen stocks were thawed at room temperature prior to the experiments and used within 24 h. After being washed in sterile saline and counted under a microscope using a hemocytometer, conidium suspension of 1 × 10⁶ colony forming unit (CFU)/ml was inoculated into potato dextrose medium, followed by incubation at 37 °C and shaking at 200 rpm for 16 h. The cultures were then treated with the antifungal drugs at different doses for 4 h, and the same amount of DMSO and PBS were added to the no-drug control. The final drug concentrations in the mycelium cultures were 10 µg/ml and 50 µg/ml for AMB and 10 µg/ml and 50 µg/ml for ND-AMB. Total RNA was extracted from 0.1 ml of mycelium cultures using a MasterPure yeast RNA purification kit (Epicentre Biotechnologies, Madison, WI), which includes a DNase treatment step to eliminate genomic DNA. Total RNA was also extracted from serial 1:10 dilutions of live A. fumigatus conidia (10⁻¹–10⁰) and Dnase treated to form a standard curve. A. fumigatus burden was analyzed with real-time PCR measurement of the A. fumigatus 18S rRNA (GenBank accession number AB008401) and quantified using a standard curve of A. fumigatus conidia.17,18

**Statistical analysis**

Statistical analyses were conducted using Excel 2010 and GraphPad Prism 6.0 software (La Jolla, Ca) with significance set at P < 0.05. Statistical evaluation utilized unpaired Student t tests for electrophysiology data and analysis of variance followed by Tukey–Kramer multiple comparison test if necessary for LDH, CBF and RNA assay. Data is expressed +/- standard error of the mean.

**Results**

**AMB vs ND-AMB induced trans-epithelial K⁺ currents in vitro**

Ussing chamber tracings were used to evaluate the AMB vs ND-AMB induced trans-epithelial K⁺ currents across the HSNE (Fig. 1A). Once the AMB (10 µg/ml) was exposed to the apical side, K⁺ currents increased immediately, demonstrating the apical membrane of HSNE had become permeable to K⁺ ions. In contrast, adding increasing concentrations of ND-AMB (10 µg/ml × 4 every 5 min = total 40 µg/ml) resulted in negligible inductions of K⁺ current in HSNE. Fig. 1B represents the summary of AMB vs ND-AMB induced trans-epithelial K⁺ current changes (n = 4, per condition). Statistically significant difference in K⁺ current changes was observed between the two groups [AMB = (107.7 ± 15.9) µA/cm² AMB (n = 4) vs ND-AMB = (2.3 ± 0.7) µA/cm² ND-AMB (n = 4); P = 0.005]. Resistance was also traced with induction of AMB vs ND-AMB. With exposing AMB (10 µg/ml) to apical side, transepithelial resistance decreased immediately, representing the K⁺ currents across the HSNE (Fig. 2A). In contrast, negligible change in transepithelial resistance was noticed after exposing increasing concentrations of ND-AMB (10 µg/ml × 4 every 5 min). Fig. 2B represents the summary of AMB vs ND-AMB induced trans-epithelial resistance changes (n = 4, per condition). ΔR (changes in transepithelial resistance, Ω cm²) following application of AMB was significantly higher than those cells exposed to ND-AMB |ΔR with AMB (n = 4) = (24.4 ± 15.7) Ω cm²; ΔR with AMB
LDH release after exposure to AMB vs ND-AMB

To quantify the release of lactate dehydrogenase (LDH), a marker of cell toxicity, cell culture media was collected after exposure (18 h) to AMB and ND-AMB. By using the positive (Triton X-100) and negative (cell culture media) controls, % cytotoxicity was measured (Fig. 3). Epithelial cells (n = 6) were exposed to toxic concentrations of AMB (75 μg/ml and 150 μg/ml) and same concentration of ND-AMB (75 μg/ml and 150 μg/ml) for 18 h. Dosages were chosen based on commercially available concentrations of AMB. For those cells incubated with AMB, LDH release was significantly increased compared to cells incubated with ND-AMB at same concentration. At 75 μg/ml, ND-AMB protected epithelial...
cells from the cytotoxicity of AMB, as determined by almost 85% reduction in lactate dehydrogenase (LDH) levels. At higher concentration (150 μg/ml) of AMB, significantly higher LDH release was noticed compared to LDH release at 75 μg/ml (P = 0.0004). NS — no statistical significance; * Statistical significance (P < 0.05).

**CBF in vitro**

CBF is an important component of mucociliary clearance and to determine whether AMB or ND-AMB deteriorate CBF, the drug was applied to the apical membranes and compared to corresponding vehicle controls. CBF was measured about 15 min after exposure to 75 μg/ml of AMB or ND-AMB. There was no difference in CBF among three groups (Control = (1.33 ± 0.04) CBF fold changes; AMB = (1.35 ± 0.44) CBF fold changes; ND-AMB = (1.34 ± 0.44) CBF fold changes, P = 0.96) (Fig. 4).

**In vitro potency of ND-AMB**

Dramatically decreased expression of *A. fumigatus* 18S rRNA was noted with 4 h exposure of 50 μg/ml of AMB and 10 μg/ml and 50 μg/ml of ND-AMB compared to controls (PBS and DMSO) and 10 μg/ml of AMB (Fig. 5) (P < 0.0001). The dose-dependent rRNA expression profiles for both AMB (10 μg/ml vs 50 μg/ml) and ND-AMB (10 μg/ml vs 50 μg/ml) were observed, reflected the killing effect of the drugs. At lower concentration (the dose of 10 μg/ml), much smaller expression profiles of *A. fumigatus* 18S rRNA were observed from ND-AMB compared to AMB (P < 0.0001): ND-AMB was significantly more potent than AMB at lower dose. At higher concentration (the dose of 50 μg/ml), there was no statistical significance in RNA expression profiles between AMB and ND-AMB: ND-AMB was as potent as AMB at higher dose (P < 0.0001).

**Discussion**

An estimated 1.5 million fungal species inhabit Earth, with the vast majority poorly described or undiscovered. Fungal rhinosinusitis (FRS) has emerged as a major challenge and the incidence of mycotic infections, number, and diversity of pathogenic fungi involved in the disease have increased dramatically in recent years with the use of newer and more potent chemotherapeutic agents and regimens. It has been stated that quality of life is significantly inferior in patients with fungal rhinosinusitis as compared with the general population and is even poorer in patients with extensive and recurrent disease with multiple disabilities and high distress in day-to-day lives. For individuals with invasive fungal infection, AMB remains a clinically imperative treatment option even after 60 years on the market. This is because AMB has several crucial advantages over other classes of antifungal agents: 1) broad-spectrum activity against a wide range of medically relevant fungal species, and 2) virtually no resistant pathological strains have developed. In contrast, resistance to azole and echinocandin antifungal drugs is now a serious concern making AMB an ideal therapy for patients with invasive fungal infections. However, AMB exhibits significant side effects such as nephrotoxicity, electrolyte abnormalities, and infusion reactions.

Oda et al have developed a novel formulation of ND containing super aggregated AMB for the treatment of fungal infections. The ND drug-delivery vehicle is a complex consisting of a scaffold protein, apolipoprotein A-I (ApoA-I), a phospholipid bilayer (PL), and AMB. Prior work has demonstrated that drugs incorporated into the ND delivery vehicle are fully solubilized and retain bioactivity compared...
to other forms of the drug. In those studies, ND-AMB loaded with AMB had high antifungal potency and was a highly efficacious treatment for invasive candidiasis in mice. Topical delivery of AMB into the sinuses may have significant advantages over intravenous infusion including the avoidance of adverse effects. However, safety remains an important consideration in topical drug delivery into the sinuses, particularly as it relates to the integrity of the epithelium and its ion transport properties, which plays an important role in host defense. Introducing a novel therapeutic to the treatment of FRS that does minimal damage to the human nasal epithelium would vastly expand the current treatment options. The goal of the present study was to determine in vitro whether ND-AMB was less disruptive to sinonasal epithelium than existing AMB with maintaining antifungal property. We observed that ND-AMB protected nasal epithelial cells from the cytotoxicity of AMB, as determined by reduction in cell membrane permeability and almost 85% reduction in lactate dehydrogenase (LDH) levels and maintained antifungal property in this in vitro model.

AMB induced cellular toxicity in the human nasal epithelia in vitro model. At 75 μg/ml of AMB, LDH release was 6.8 time higher than LDH release after exposure to the same concentration of ND-AMB. The commercially available concentration of AMB solution is 100 μg/ml, which is the most commonly recommended concentration for patient use in sinus irrigation. A pilot study by Shirazi et al demonstrated that amphotericin B solution (100 μg/ml) was ineffective in killing fungi in vitro over a 6-week period. Concentrations of 300 μg/ml and 200 μg/ml had fungicidal effect on 10 fungi commonly found in patients with fungal-related CRS after 5 and 6 weeks of treatment, respectively. They suggested that higher concentrations of topical amphotericin B need to be tested for efficacy. However, based on our findings, it is highly likely that those concentrations are significantly toxic to airway epithelial cells and thus requires further investigation. Regarding the underlying mechanism, the ratio of AMB to phospholipid bilayer (PL) was identified as an important modulator of protective activity. ND-AMB with a low AMB to PL ratio reduced permeability of the epithelium and therefore it appears that ND extracts AMB from the plasma membrane, rather than simply blocking electrically conductive channels (pores) by vehicles. Burgess et al showed the ability of ND-AMB to restore membrane resistance that had been previously compromised by exposure to AMB. We have also demonstrated that an AMB formulation composed of super aggregated AMB contained within the ND drug-delivery bioparticle has potency against A. fumigatus equivalent to the AMB formulation. It seems that ND-AMB is a highly efficacious treatment for FRS.

This novel therapy has important applications in FRS as there are no clinically effective topical fungal therapies currently available, especially in patients with IFS. Further studies should be performed to determine the efficacy of topical ND-AMB irrigation in in vivo animal models with fungal rhinosinusitis, and to measure any advantages of this approach.

Conclusions

ND-AMB protects human nasal epithelial membranes from AMB toxicity by reducing apical cell K⁺ permeability and LDH release while maintaining uncompromised antifungal property compared to AMB. Topical delivery of ND-AMB into the sinonasal epithelium could expand the current treatment options for FRS as there are no clinically effective topical fungal therapies available.

Research support

This work was supported by National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (1 R01 HL133006-01) and National Institute of Diabetes and Digestive and Kidney Diseases (5P30DK072482-04, CF Research Center Pilot Award) to B.A.W., and John W. Kirklin Research and Education Foundation Fellowship Award and UAB Faculty Development Research Award to D.Y.C.
Conflict of interest/Financial disclosures

Bradford A. Woodworth, M.D. is a consultant for Olympus and Cook Medical.

Acknowledgement

ND-AMB was received as a gift from Michael Oda PHD at University of California at San Francisco — Children’s Hospital at Oakland Research Institute (UCSF-CHORI).

References

1. Callejas CA, Douglas RG. Fungal rhinosinusitis: what every allergist should know. Clin Exp Allergy. 2013;43:835–849.

2. Schubert MS. Allergic fungal sinusitis: pathophysiology, diagnosis and management. Med Mycol. 2009;47(suppl 1): S24–S330.

3. Low CY, Rotstein C. Emerging fungal infections in immuno-compromised patients. F1000 Med Rep. 2011;3:14.

4. Hamill RJ. Amphotericin B formulations: a comparative review containing amphotericin B as a drug delivery platform with cell membrane protective properties. Antimicrob Agents Chemother. 2009;53:1420–1426.

5. Burgess BL, Cavigiolio G, Fannucchi MV, Illek B, Forte TM, Oda MN. A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties. Int J Pharm. 2010;399:148–155.

6. Burgess BL, He Y, Baker MM, et al. NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency. Int J Nanomedicine. 2013;8:4733–4743.

7. Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO. Reconstituted high density lipoprotein enriched with the polyclonal antibody amphotericin B. J Lipid Res. 2006;47:260–267.

8. Bhargave G, Woodworth BA, Xiong G, Wolfe SG, Antunes MB, Cohen NA. Transient receptor potential vanilloid type 4 channel expression in chronic rhinosinusitis. Am J Rhinol. 2008;22:7–12.

9. Woodworth BA, Antunes MB, Bhargave G, Palmer JN, Cohen NA. Murine tracheal and nasal septal epithelium for air-liquid interface cultures: a comparative study. Am J Rhinol. 2007;21:533–537.

10. Woodworth BA, Tamashiro E, Bhargave G, Cohen NA, Palmer JN. An in vitro model of Pseudomonas aeruginosa biofilms on viable airway epithelial cell monolayers. Am J Rhinol. 2008;22:235–238.

11. Antunes MB, Woodworth BA, Bhargave G, et al. Murine nasal septa for respiratory epithelial air-liquid interface cultures. Biotechniques. 2007;43:195–196, 198, 200 passim.

12. Alexender NS, Hatch N, Zhang S, et al. Rosuvastatin has salutary effects on mucociliary transport and inflammation in sinonasal epithelium. Laryngoscope. 2011;121:1313–1319.

13. Cohen NA, Zhang S, Sharp DB, et al. Cigarette smoke condensate inhibits transepithelial chloride transport and ciliary beat frequency. Laryngoscope. 2009;119:2269–2274.

14. Zhang S, Skinner D, Hicks SB, et al. Sinupret activates CFTR and TMEM16A-dependent transepithelial chloride transport and improves indicators of mucociliary clearance. PLoS One. 2014;9:e104090.

15. Cowley EA, Linsell P. Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. J Physiol. 2002;538:747–757.

16. Mattila PE, Metz AE, Rapaka RR, Bauer LD, Steele C. Dectin-1Fc targeting of Aspergillus fumigatus beta-glucans augments innate defense against invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2008;52:1171–1172.

17. Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother. 2001;45:3474–3481.

18. Clancy CJ, Nguyen MH. Invasive sinus aspergillosis in apparently immunocompetent hosts. J Infect. 1998;37:229–240.

19. Denning DW, Evans EG, Kibbler CC, et al. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. Eur J Clin Microbiol Infect Dis. 1997;16:424–436.

20. Srivastava RM, Rijuneeta, Gupta AK, Patro SK, Avasthi A. Quality of life, disability scores, and distress index in fungal rhinosinusitis. Med Mycol. 2014;52:706–714.

21. Beyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann Pharmacother. 2012;46:1086–1096.

22. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009;9:789–795.

23. Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance. Fungal Genet Biol. 2010;47:117–126.

24. Shirazi MA, Stankiewicz JA, Kammeyer P. Activity of nasal amphotericin B irrigation against fungal organisms in vitro. Am J Rhinol. 2007;21:145–148.